[Diagnostic implications of detecting antibodies to angiotensin-converting enzyme and its substrates].
The results of the analysis of diagnostic significance of examination of natural antibodies (Nab) to agiotensin-converting enzyme (ACE) and its substrates in the serum of hypertensive patients indicate that concentration of Nab to ACE differ from this mean concentration in donors. An elevated level of Nab to ACE may be considered as a compensatory reaction to increased content of the enzyme in vascular endothelium and blood flow. The same patients were examined for antibodies to peptide angiotensin II (AT-II). Enzyme immunoassay has shown that a significantly elevated level of antibodies to AT-II was only in 5 examinees. The same patients had also high Nab to ACE. The study of a group of ischemic heart disease patients with adverse effects attributed to bronchial affection treated with enalapril and diroton (ACE inhibitors) demonstrates that deterioration of cough and external respiration function is not related to exacerbation of existing chronic pulmonary inflammation. None of the patients had elevated body temperature or inflammatory changes in the blood, other signs of inflammation. Enzyme immunoassay also proved that the initial level of Nab equaled mean value for donors or was insignificantly lower. Blood serum patients with side effects contained a significantly (p < 0.02) elevated quantities of Nab to bradikinin vs initial values. Thus, the proposed method of solid phase enzyme immunoassay quantifies Nab to ACE and its substrates in the patients.
D S
DS
Kostrikin
O N
ON
Panchenko
M A
MA
Miagkova
M L
ML
Stanislav
O A
OA
Kost
I I
II
Nikol'skaia
A V
AV
Pogozheva
I P
IP
Kiselev
D I
DI
Valuev
D000804:Angiotensin II / Q000276:immunology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D001249:Asthma / Q000097:blood* / Q000139:chemically induced / Q000201:enzymology; D001323:Autoantibodies / Q000097:blood*; D001920:Bradykinin / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D007703:Peptidyl-Dipeptidase A / Q000276:immunology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D001323:Autoantibodies; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A; D001920:Bradykinin